$APTO announced that the  U.S. Food and Drug Administration    has granted IND allowance for the initiation of a Phase 1a/b clinical study of CG-806, the company’s highly potent, oral FLT3/BTK inhibitor, in patients with acute myeloid leukemia (AML)

#daytrading #stocks